



PATENT
Customer No. 22,852
Attorney Docket No. 6832.0012

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
David J. BALLANCE et al.) Group Art Unit: 1653
Application No.: 09/832,501) Examiner: Hope A. Robinson
Filed: April 12, 2001)
For: ALBUMIN FUSION PROTEINS)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In a restriction requirement dated August 26, 2003, the Examiner required restriction under 35 U.S.C. § 121 between the following groups:

Group I Claims 1-21, drawn to an albumin fusion protein comprising a therapeutic protein X and albumin (SEQ ID NO: 18), class 424, subclass 192.1;

Group II Claims 22-25, drawn to a method of treating a disease or disorder in a patient, class 514, subclass 12;

Group III Claim 26, drawn to a method of extending the shelf life of therapeutic protein X, class 435, subclass 449;

Group IV Claims 27-29, drawn to a nucleic acid molecule, class 536, subclass 23.4;

Group V Claims 30-50 and 60, drawn to an albumin fusion protein comprising an interferon alpha polypeptide, classified in class 424, subclass 192.1;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Group VI Claims 51-54, drawn to a method of treating a disease or disorder in a patient using the fusion protein comprising an interferon alpha polypeptide, classified in class 514, subclass 12;

Group VII Claim 55, drawn to a method of extending the shelf life of an interferon alpha polypeptide, classified in class 435, subclass 449; and

Group VIII Claims 56-59, drawn to a nucleic acid molecule encoding an albumin fusion protein comprising an interferon alpha polypeptide, classified in class 536, subclass 23.4.

Applicants provisionally elect to prosecute Group I, claims 1-21, drawn to an albumin fusion protein comprising a therapeutic protein X and albumin (SEQ ID NO: 18), with traverse.

According to MPEP § 803, there are two requirements that must be met before a proper restriction requirement may be made: (1) the inventions must be independent or distinct as claimed; and (2) there must be a serious burden on the Examiner if restriction is not required. Applicants respectfully submit that the Office has failed to establish the second requirement set forth in MPEP § 803.

In the present invention, Groups I-IV relate to an albumin fusion protein comprising a therapeutic protein X and albumin. Groups V-VIII mirror Groups I-IV except that Groups V-VIII relate to an albumin fusion protein comprising an interferon alpha polypeptide. A search and examination of the subject matter of any one of Groups I-IV would necessarily encompass a search for the albumin fusion protein comprising an interferon alpha polypeptide of Groups V-VIII, and any additional search would not impose a serious burden upon the Examiner.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

It is therefore respectfully requested that the restriction requirement be reconsidered. In the event that the restriction requirement is maintained, Applicants reserve the right to file divisional applications on the non-elected inventions and/or to request rejoinder of appropriate claims once the subject matter of claims 1-21 is found allowable.

Applicants filed a Change of Correspondence Address on September 22, 2003.

Kindly direct all future correspondence for the instant application to:

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.
1300 I Street, N.W.
Washington, D.C. 20005-3315
Telephone: (202) 408-4000
Fax: (202) 408-4400

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: Charles E. Van Horn
Charles E. Van Horn
Reg. No. 40,266

Dated: September 25, 2003

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER L.L.P.

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com